43.78
price down icon2.17%   -0.97
after-market Handel nachbörslich: 43.78
loading

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
Nov 18, 2024

State of New Jersey Common Pension Fund D Reduces Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Osteogenesis Imperfecta Treatment Market 2024-2031: Global - openPR

Nov 15, 2024
pulisher
Nov 14, 2024

How To Trade (RARE) - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 14, 2024

RTW INVESTMENTS, LP Adjusts Stake in Ultragenyx Pharmaceutical I - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Ultragenyx Pharmaceutical's SWOT analysis: pipeline progress boosts rare disease stock - Investing.com

Nov 13, 2024
pulisher
Nov 12, 2024

Ultragenyx posts trial data backing Phase 3 design for Angelman syndrome therapy - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from Canaccord Genuity Group - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Ultragenyx: Ready For More Growth After Q3 Earnings Beat (NASDAQ:RARE) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 12, 2024
pulisher
Nov 11, 2024

Research Analysts Offer Predictions for RARE FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates - MSN

Nov 10, 2024
pulisher
Nov 09, 2024

Ultragenyx posts data for Angelman syndrome therapy (RARE:NASDAQ) - Seeking Alpha

Nov 09, 2024
pulisher
Nov 09, 2024

Ultragenyx Presents Positive Update on GTX-102 Angelman - GlobeNewswire

Nov 09, 2024
pulisher
Nov 09, 2024

Ultragenyx's Angelman Treatment Shows 80% Patient Improvement in Phase 1/2 Trial | RARE Stock News - StockTitan

Nov 09, 2024
pulisher
Nov 08, 2024

What is Wedbush's Estimate for RARE FY2024 Earnings? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Leerink Partnrs Has Negative Outlook of RARE FY2024 Earnings - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

What is HC Wainwright's Estimate for RARE FY2024 Earnings? - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024
pulisher
Nov 07, 2024

What is HC Wainwright's Estimate for RARE Q1 Earnings? - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 07, 2024
pulisher
Nov 06, 2024

Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Ultragenyx Pharma stock target raised, retains buy on strong revenue growth - Investing.com India

Nov 06, 2024
pulisher
Nov 06, 2024

HC Wainwright Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $95.00 - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Ultragenyx Pharma stock target raised, retains buy on strong revenue growth By Investing.com - Investing.com South Africa

Nov 06, 2024
pulisher
Nov 06, 2024

Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

International Assets Investment Management LLC Boosts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Ultragenyx: Excellent Company, Lackluster Stock (NASDAQ:RARE) - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Ultragenyx Reports Strong Q3 Growth and Milestones - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Pharmaceutical reports an over 40% increase in Q3 revenue - North Bay Business Journal

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Pharmaceutical Q3 2024 Earnings Preview - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings: Revenue S - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast - Benzinga

Nov 04, 2024
pulisher
Nov 03, 2024

Trend Tracker for (RARE) - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 03, 2024

Emerald Advisers LLC Raises Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 03, 2024
pulisher
Nov 02, 2024

abrdn plc Sells 31,441 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? - Insider Monkey

Nov 01, 2024
pulisher
Oct 31, 2024

Oversold Conditions For Ultragenyx Pharmaceutical (RARE) - Nasdaq

Oct 31, 2024
pulisher
Oct 31, 2024

Pinnacle Associates Ltd. Has $6.63 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Ultragenyx Pharmaceutical (RARE) to Release Earnings on Tuesday - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update - The Manila Times

Oct 30, 2024
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Kapitalisierung:     |  Volumen (24h):